COVID-19

[Signal Transduction and Targeted Therapy] Using wild-type and human ACE2 knock-in mouse models, investigators found a single dose of rVSV-SARS-CoV could elicit strong humoral immune response via both intranasal and intramuscular routes.

[Communications Medicine] The authors reported a series of ten COVID-19 patients with audiovestibular symptoms such as hearing loss, vestibular dysfunction and tinnitus.

[NPJ Regenerative Medicine] Scientists performed a systematic review of clinical studies investigating different types of stem cells as treatments for COVID-19 and ARDS to evaluate the safety and potential efficacy of cell therapy.

[Scientific Reports] Researchers evaluated novel protein subunit vaccine formulations containing a resistin-trimerized spike antigen, SmT1.

[Pfizer, Inc.] Pfizer, Inc. and BioNTech SE announced that the FDA has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age.

[Vitti Labs (PR Newswire, Inc.)] Vitti Labs announced that the US FDA has approved its Investigational New Drug (IND) application to conduct Phase II Clinical Trials using a combination of umbilical cord mesenchymal stem cell and umbilical cord mesenchymal stem cell exosomes for the treatment of Acute Respiratory Distress Syndrome associated with COVID-19.